Bookmark and Share

Compound Summary for: CID 104850

rimonabant

Also known as: Acomplia; Zimulti; 168273-06-1; Rimoslim; Slimona; SR 141716; Riobant; UNII-RML78EN3XE; SR141716
Molecular Formula: C22H21Cl3N4O   Molecular Weight: 463.78734   InChIKey: JZCPYUJPEARBJL-UHFFFAOYSA-N
Rimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil. It was rejected for approval for use in the United States. This decision was made after a U.S. advisory panel recommended the medicine not be approved because it may increase suicidal thinking and depression.   From: DrugBank
Show subcontent titlesTable of Contents
Identification
Related Records
show all 3 sub-sections (Related Compounds with Annotation, Related Compounds, Related Substances)
Use and Manufacturing
Pharmacology
Literature
Patents
Biomolecular Interactions and Pathways
Biological Test Results
Classification
Chemical and Physical Properties
_ _